change in renal function and its predictors in patients with HF is crucial to establishing better therapy for both HF and cardiorenal syndrome. 11 However, to our knowledge, there are few reports on the risk for impaired renal function and few reports of long-term follow-up to examine if renal dysfunction has increased in patients with HF. Therefore, the purpose of this study was to reveal the long-term changes in renal function in patients with IDCM without renal insufficiency at initial diagnosis. Furthermore, we examined various clinical parameters as the predictive values of the clinical course of renal function.
Methods

Patient Population
We performed a retrospective analysis of patients with IDCM who were referred to Niigata University Medical and Dental Hospital between 1983 and 2003. The diagnosis of IDCM was based on careful medical history, physical examination, chest radiography, electrocardiography, blood test, echocardiography, and cardiac catheterization. All patients underwent cardiac catheterization after improvement of HF symptoms. All patients were free of ischemic heart disease, valvular heart disease, congenital heart disease, and other cardiomyopathies. Patients who had renal insufficiency at the first diagnosis were excluded. Renal insufficiency was defined as estimated creatinine clearance (eCcr) <60 ml/min, calculated by using the Cockroft-Gault equation: [(140-age) × body weight (kg)]/[72 × serum creatinine (mg/dl)], multiplied by 0.85 for women. 12, 13 Follow-up IDCM patients underwent periodic medical checkups and received the standard therapy, ACEI, ARB, and -blockers, by the hospital's cardiologists. The decision to use each drugs in individual cases was left to the attending physician. The endpoint of follow-up was the occurrence of renal insufficiency defined as eCcr <60 ml/min. The non-survivors were considered as censored cases at that point in time. Data including frequency of admission for HF, left ventricular ejection fraction (LVEF), and diastolic left ventricular diameter were recorded just before the occurrence of renal insufficiency as follow-up data. The ratio of LVEF improvement (∆LVEF) was calculated as: 100 × [(LVEF just before the end point of follow-up) -(LVEF at initial diagnosis)]/ (LVEF at initial diagnosis). The existence of hypotension was defined as systolic blood pressure (BP) <80 mmHg persisting for at least 6 months before the occurrence of renal insufficiency.
Statistical Analysis
Patients' characteristics were expressed as mean ± standard error of mean for continuous variables and as numbers (proportions) for categorical variables. Cumulative event proportion was evaluated by Kaplan-Meier survival analysis. Potential risk factors for the occurrence of renal insufficiency were evaluated by Cox proportional hazards regression for the baseline data at initial diagnosis, and by logistic regression for the data observed during follow-up. An ageadjusted model and additional forward selection method were used for both the Cox and logistic regression analyses. All analyses were performed using SPSS version 12.0J (Chicago, IL, USA). Two-sided statistical significance was taken as p<0.05.
Results
Baseline Patients' Characteristics
The baseline clinical characteristics of 70 patients with IDCM are summarized in Table 1 (17 women, 53 men; mean age 48.0±1.6 years). Eight (11.4%) patients also had diabetes mellitus (DM), 12 (17.1%) had hypertension, and 17 (24.3%) had atrial fibrillation. Mean LVEF measured by cardiac catheterization was 35.84±1.15% and the mean cardiac index (CI) was 2.90±0.10 L·min -1 ·m -2 . The mean eCcr was 94.57±4.69 ml/min and >60 ml/min in all patients.
Longitudinal Change in Renal Function in Patients With IDCM
The Kaplan-Meier survival curve showed the time and cumulative proportion without the occurrence of renal insufficiency. The calculated cumulative proportion of eventfree promotion at 8 and 20 years follow-up was 80.2% and 50.2%, respectively (Fig 1) .
Potential Risk Factors at Initial Diagnosis for the Occurrence of Renal Insufficiency
Potential risk factors at the initial diagnosis for the occurrence of renal insufficiency are summarized in Table 2 . Age at the initial diagnosis (hazard ratio 1.112, p<0.001) was the factor most strongly associated with the occurrence of renal insufficiency. The presence of urinary protein at the initial diagnosis (p=0.079) meant that impaired renal function was likely to occur. No other risk factors were identified in this analysis as risk factors at the initial diagnosis.
Predictors for the Occurrence of Renal Insufficiency During Follow-up
The characteristics of the 70 patients with IDCM during the follow-up period are summarized in Table 3 . Fifty-eight (82.9%) tolerated long-term oral -blocker therapy; 41 (58.6%) were treated with metoprolol, 10 (14.2%) were treated with carvedilol, 4 (5.7%) were treated with atenolol, and other -blockers were used in 4 patients (5.7%). Mean maintenance doses were 54.1±4.5 mg for metoprolol, 9.6± 1.7 mg for carvedilol, and 18.8±3.6 mg for atenolol. Reasons for not using -blocker therapy were bradyarrhythmia (4.3%), bronchial asthma (2.8%), hypotension (1.4%), and unknown (8.6%). Predictors for the occurrence of renal insufficiency during follow-up are summarized in Table 4 . The occurrence of renal insufficiency was significantly higher in patients with high frequency of admission for the exacerbation of HF (odds ratio 1.750, p=0.004) and patients with continuous hypotension (odds ratio 353.7, p=0.006). Beta-blocker therapy was the predictor for preventing the occurrence of renal insufficiency (odds ratio 0.102, p= 0.012). The ratio of patients receiving ACEI and/or ARB was 87.1%, and these were not associated with elevated risk of renal insufficiency in this study.
Longitudinal Change in Renal Function Because of the Ratio of LVEF Improvement
The result of age-adjusted logistic regression analysis suggested ∆LVEF had a tendency to be a negative predictor (odds ratio 0.980, p=0.010) for the occurrence of renal insufficiency. Fig 2 shows the differences in the Kaplan-Meier survival curve between Group ∆LVEF ≥20% and Group ∆LVEF <20%. There was a significant decrease in the occurrence of renal insufficiency in Group ∆LVEF ≥20% compared with Group ∆LVEF <20% (log-rank, p=0.011). The respective calculated cumulative proportion without the occurrence of renal insufficiency at 8 and 20 years followup was 96.7% and 72.7% in ∆LVEF ≥20%, and 72.1% and 30.2% in Group ∆LVEF <20%.
Discussion
The importance of this study is that it reveals the longitu- Table 1 .
∆LVEF <20 ∆LVEF ≥20 Tables 1,3 .
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dinal change of renal function in patients with IDCM without renal insufficiency at initial diagnosis; renal insufficiency, as defined by eCcr <60 ml/min, occurred in 20% during the first 8 years of follow-up and in 50% at the 20-year follow-up. In addition, we demonstrated that high frequency of admission for the exacerbation of HF, hypotension during the follow-up period, and not taking -blocker therapy are prognostic factors for the worsening of renal function in these patients. There are strong interactions between cardiovascular and renal disease. Renal dysfunction is an independent risk factor for the development of cardiovascular disease. 12, [19] [20] [21] Decreased GFR has consistently been found to be an independent risk factor for cardiovascular disease outcomes and all-cause mortality in patients with HF. 13, 14 Our data also indicated that 27% of patients who showed eGFR <60 ml/min died from cardiovascular disease, compared with 6% of patients who showed eGFR >60 ml/min, during follow-up (data not shown). Because the risk of cardiovascular events becomes evident at an estimated GFR <60 ml/min, in the present study we defined cCcr <60 ml/min as renal insufficiency. 19, 20, 22, 23 Our results suggest that in IDCM patients without renal insufficiency at their initial diagnosis, renal insufficiency occurs in 20% of during the first 8 years of follow-up and, surprisingly, in 50% at 20-year follow-up. DM is estimated to increase the risk of end-stage renal disease approximately 12-fold. 24 Although the proportion of the progression of renal disease in patients with DM is diverse, in general, renal function shows stable or hyper filtration for 10-15 years after diagnosis, and progression to renal insufficiency occurs after a follow-up of 20 years. 24, 25 Thus, our data suggests that the clinical course of renal function in patients with IDCM is likely to be worse.
Age at initial diagnosis was the factor most strongly associated with the occurrence of renal dysfunction. After stratification for age, high frequency of admission for the exacerbation of HF, hypotension, and -blocker therapy remain associated with a change of renal function. Several reports have demonstrated that worsening renal function occurs frequently among hospitalized HF patients and is associated with worse outcomes. [15] [16] [17] Forman et al speculated that renal deterioration was associated with inherent mechanisms of disease or to the impact of therapy administered on admission, because the worsening of renal function occurs early after admission. Our findings are consistent with, and could extend their findings; once patients were admitted, renal function worsened and did not recover completely to the level before admission, even after deteriorating HF was improved. In other words, renal function worsens not only sequentially but also step-by-step in accordance with admission because of deterioration of HF. Although the precise reasons are unknown from this study, there are some explanations. The use of diuretics for patients with HF is still controversial in terms of renal protection and is potentially less likely to improve renal function. We tried to evaluate the relationship between the use of diuretics and renal function, but because of fluctuations of the doses and use in some patients, correcting the data throughout the follow-up period was difficult to do retrospectively. Further study is needed to clarify this point. Another explanation for worsening renal function is the deterioration of HF itself. The renin -angiotensin system and sympathetic nerve activity became excessively stimulated during episodes of acute decompensation and both cause impaired renal function. 26 Neither ACEI nor ARB showed a significant relationship with renal function in our study. The beneficial effects of both agents on renal function are well known from large clinical trails. 27, 28 In this study, 87.1% of the patients were treated with ACEI and/or ARB and this high proportion of the patients might have affected the analysis.
Braam et al suggest that the cardiorenal connection is an interactive network with positive feedback loops, including not only extracellular fluid volume and BP, but also the renin -angiotensin system, the balance between nitric oxide and reactive oxygen species, inflammation, and the sympathetic nervous system. 12 The mechanisms of HF-induced/ associated impaired renal function are diverse and not welldefined. 2 Hemodynamic abnormalities, such as hypotension or low cardiac output, and neurohumoral factors, including endothelin, nitric oxide, prostaglandin and natriuretic peptides, are thought to play an important role. 10 Our results also imply that hypotension has an important role in the progression of renal dysfunction. The CI at initial diagnosis was not associated with changes in renal function. Lungman et al demonstrated that renal blood flow could be preserved if the CI remained above 1.5 L·min -1 ·mm -1 . 29 The mean CI at initial diagnosis in this study was L·min -1 ·mm -1 , and renal blood flow may have been preserved. However, because there are no data on cardiac catheterization during the follow-up period, we could not determine the relationship between subsequent CI and renal function. However, in our study there was a significant difference in the progression of renal insufficiency between patients whose ∆LVEF improved more than 20% and those whose ∆LVEF improved less than 20%. Beta-blocker therapy, which has resulted in improved survival, morbidity, ejection fraction, and rate of hospitalization, 30 is also associated with beneficial results on renal function. These facts suggest that improvement of hemodynamic abnormalities has favorable effects on renal function in patients with HF via modulation of several factors.
Study Limitations
First, this was not a randomized, prospective study. Second, the number of subjects was small, and this might have affected the statistical analyses. Larger trials must be conducted to confirm our results.
Clinical Implications
The most important is that the clinical course of renal function in patients with IDCM is less likely to be good, even if renal function is preserved at initial diagnosis. We also must recognize that admission, hypotension, and not taking -blocker therapy are associated with poor prognosis in renal function. We need to take meticulous care of HF patients and to choose therapies that offer renal protection for them. A prospective study is also needed to establish the best therapy for long-term management.
